0001493152-24-007873.txt : 20240226 0001493152-24-007873.hdr.sgml : 20240226 20240226184112 ACCESSION NUMBER: 0001493152-24-007873 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240222 FILED AS OF DATE: 20240226 DATE AS OF CHANGE: 20240226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vaknin Rachel CENTRAL INDEX KEY: 0001923217 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19871 FILM NUMBER: 24681097 MAIL ADDRESS: STREET 1: DROR 3/10 CITY: ZICHRON YAAKOV STATE: L3 ZIP: 3090216 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Microbot Medical Inc. CENTRAL INDEX KEY: 0000883975 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 943078125 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 BUSINESS PHONE: 908-938-5561 MAIL ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 FORMER COMPANY: FORMER CONFORMED NAME: STEMCELLS INC DATE OF NAME CHANGE: 20000524 FORMER COMPANY: FORMER CONFORMED NAME: CYTOTHERAPEUTICS INC/DE DATE OF NAME CHANGE: 19930328 4 1 ownership.xml X0508 4 2024-02-22 0 0000883975 Microbot Medical Inc. MBOT 0001923217 Vaknin Rachel C/O MICROBOT MEDICAL INC. 288 GROVE STREET, SUITE 388 BRAINTREE MA 02184 0 1 0 0 Chief Financial Officer 0 Stock Option (Right to Buy) 1.2684 2024-02-22 4 A 0 17500 0 A 2034-02-22 Common Stock, par value $0.01 per share 17500 17500 D Stock Option (Right to Buy) 1.2684 2024-02-22 4 A 0 17500 0 A 2024-02-22 2034-02-22 Common Stock, par value $0.01 per share 17500 17500 D The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 22, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. /s/ Rachel Vaknin 2024-02-26